Impact of Anticoagulation on Mortality and Resource Utilization Among Critically Ill Patients with Major Bleeding in the ICU
CCCF ePoster library. Fernando S. 11/13/19; 283396; EP99
Dr. Shannon Fernando
Dr. Shannon Fernando
Login now to access Regular content available to all registered users.

You may also access this content "anytime, anywhere" with the Free MULTILEARNING App for iOS and Android
Abstract
Rate & Comment (0)
ePoster
Topic: Retrospective or Prospective Cohort Study or Case Series

Garrick Mok, MD1; Shannon M. Fernando, MD, MSc1,2; Lana A. Castellucci, MD, MSc3,4,5; Dar Dowlatshahi, MD, PhD4,5,6; Bram Rochwerg, MD, MSc7,8; Daniel I. McIsaac, MD, MPH4,5,9; Marc Carrier, MD, MSc3,4,5; Philip S. Wells, MD, MSc3,4,5; Sean M. Bagshaw, MD, MSc10; Dean A. Fergusson, PhD, MHA4,5; Peter Tanuseputro, MD, MHSc4,5,11; Kwadwo Kyeremanteng, MD, MHA1,5,11      

From the 1Department of Emergency Medicine, University of Ottawa, Ottawa, ON; 2Division of Critical Care, Department of Medicine, University of Ottawa, Ottawa, ON; 3Division of Hematology, Department of Medicine, University of Ottawa, Ottawa, ON; 4School of Epidemiology and Public Health, University of Ottawa, Ottawa, ON; 5Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, ON; 6Division of Neurology, Department of Medicine, University of Ottawa, Ottawa, ON; 7Department of Medicine, Division of Critical Care, McMaster University, Hamilton, ON; 8Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON; 9Department of Anesthesiology and Pain Medicine, University of Ottawa, Ottawa, ON; 10Department of Critical Care Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB; 11Division of Palliative Care, Department of Medicine, University of Ottawa, Ottawa, ON.


INTRODUCTION AND OBJECTIVES:
Patients with major bleeding (e.g. gastrointestinal bleeding, and intracranial hemorrhage [ICH]) are commonly encountered in the intensive care unit (ICU). A growing number of patients are on either oral or parenteral anticoagulation (AC), but the impact of AC on outcomes of patients with major bleeding is unknown. We sought to examine this association and evaluate for potential subgroup effects between patients taking Warfarin as compared to those taking Direct Oral Anticoagulants (DOACs).        
 
METHODS: We analyzed a prospectively collected registry (2011-2016) from two hospitals capturing consecutive ICU patients admitted with major bleeding. “Major bleeding” was defined by the International Society on Thrombosis and Haemostasis criteria. The primary outcome, in-hospital mortality, was analyzed using a multivariable logistic regression model. Secondary outcomes included discharge to long-term care among survivors, total hospital length of stay (LOS) among survivors, and total hospital costs. 
 
RESULTS: 1,477 patients with major bleeding were included. AC use was found among 215 total patients (14.6%). Among OAC patients (n = 181), 141 (77.9%) had used Warfarin, and 40 (22.1%) had used a DOAC. 484 patients (32.8%) died in-hospital. AC use was associated with higher in-hospital mortality (adjusted odds ratio [OR]: 1.50 [1.17-1.93]). Among survivors to discharge, AC use was associated with higher discharge to long-term care (adjusted OR: 1.73 [1.18-2.57]), prolonged median LOS (19 days vs. 16 days, P = 0.03), and higher mean costs ($69,273 vs. $58,156, P = 0.02). With regards to OAC, a higher proportion of ICH was seen among patients on Warfarin (39.0% vs. 32.5%), as compared to DOACs. No difference in mortality was seen between DOACs and Warfarin (adjusted OR: 0.84 [0.40-1.72]). Patients with major bleeding on Warfarin had longer median LOS (11 days vs. 6 days, P = 0.03) and higher total costs ($51,524 vs. $35,176, P < 0.01) than patients on DOACs. 
 
CONCLUSION: Among ICU patients admitted with major bleeding, pre-admission anticoagulation use was associated with increased hospital mortality, and prolonged LOS and costs among survivors. As compared to DOACs, patients with Warfarin-associated major bleeding had increased LOS and costs. These findings have important implications in the care of ICU patients with major bleeding.


Image Image Image

1. Lip GYH, Banerjee A, Boriani G, et al. Antithrombotic Therapy for Atrial Fibrillation: CHEST Guideline and Expert Panel Report. Chest. 2018;154(5):1121-1201.
2. Holbrook A, Schulman S, Witt DM, et al. Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e152S-e184S.
3. Lloyd-Jones D, Adams RJ, Brown TM, et al. Executive summary: heart disease and stroke statistics--2010 update: a report from the American Heart Association. Circulation. 2010;121(7):948-954.
4. Huang W, Goldberg RJ, Anderson FA, Kiefe CI, Spencer FA. Secular trends in occurrence of acute venous thromboembolism: the Worcester VTE study (1985-2009). Am J Med. 2014;127(9):829-839.e825.
5. Shroff GR, Solid CA, Herzog CA. Atrial fibrillation, stroke, and anticoagulation in Medicare beneficiaries: trends by age, sex, and race, 1992-2010. J Am Heart Assoc. 2014;3(3):e000756.
6. Connolly SJ. Anticoagulant-Related Bleeding and Mortality. J Am Coll Cardiol. 2016;68(23):2522-2524.
7. Beyer-Westendorf J, Forster K, Pannach S, et al. Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry. Blood. 2014;124(6):955-962.
8. Beyer-Westendorf J, Ebertz F, Forster K, et al. Effectiveness and safety of dabigatran therapy in daily-care patients with atrial fibrillation. Results from the Dresden NOAC Registry. Thromb Haemost. 2015;113(6):1247-1257.
9. Shah BR, Scholtus E, Rolland C, Batscheider A, Katz JN, Nilsson KR, Jr. A rapid evidence assessment of bleed-related healthcare resource utilization in publications reporting the use of direct oral anticoagulants for non-valvular atrial fibrillation. Curr Med Res Opin. 2018:1-25.
10. Loo SY, Dell'Aniello S, Huiart L, Renoux C. Trends in the prescription of novel oral anticoagulants in UK primary care. Br J Clin Pharmacol. 2017;83(9):2096-2106.
11. Xu Y, Schulman S, Dowlatshahi D, et al. Direct Oral Anticoagulant- or Warfarin-Related Major Bleeding: Characteristics, Reversal Strategies, and Outcomes From a Multicenter Observational Study. Chest. 2017;152(1):81-91.
12. Inayet N, Amoateng-Adjepong Y, Upadya A, Manthous CA. Risks for developing critical illness with GI hemorrhage. Chest. 2000;118(2):473-478.
13. Oppenheim-Eden A, Glantz L, Eidelman LA, Sprung CL. Spontaneous intracerebral hemorrhage in critically ill patients: incidence over six years and associated factors. Intensive Care Med. 1999;25(1):63-67.
14. Udy AA, Vladic C, Saxby ER, et al. Subarachnoid Hemorrhage Patients Admitted to Intensive Care in Australia and New Zealand: A Multicenter Cohort Analysis of In-Hospital Mortality Over 15 Years. Crit Care Med. 2017;45(2):e138-e145.
15. Fernando SM, Reardon PM, Rochwerg B, et al. Sepsis-3 Septic Shock Criteria and Associated Mortality Among Infected Hospitalized Patients Assessed by a Rapid Response Team. Chest. 2018;154(2):309-316.
16. Fernando SM, Reardon PM, Dowlatshahi D, et al. Outcomes and Costs of Patients Admitted to the ICU Due to Spontaneous Intracranial Hemorrhage. Crit Care Med. 2018.
17. Fernando SM, Rochwerg B, Reardon PM, et al. Emergency Department disposition decisions and associated mortality and costs in ICU patients with suspected infection. Crit Care. 2018;22(1):172.
18. Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3(4):692-694.
19. Schulman S, Angeras U, Bergqvist D, Eriksson B, Lassen MR, Fisher W. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients. J Thromb Haemost. 2010;8(1):202-204.
20. Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use with administrative data. Med Care. 1998;36(1):8-27.
21. Marshall JC, Cook DJ, Christou NV, Bernard GR, Sprung CL, Sibbald WJ. Multiple organ dysfunction score: a reliable descriptor of a complex clinical outcome. Crit Care Med. 1995;23(10):1638-1652.
22. Reis Miranda D, Moreno R, Iapichino G. Nine equivalents of nursing manpower use score (NEMS). Intensive Care Med. 1997;23(7):760-765.
23. Kramer AA, Dasta JF, Kane-Gill SL. The Impact of Mortality on Total Costs Within the ICU. Crit Care Med. 2017;45(9):1457-1463.
24. Blough DK, Ramsey SD. Using Generalized Linear Models to Assess Medical Care Costs. Health Serv Outcomes Res Methodol. 2000;1(2):185-202.
25. Gregori D, Petrinco M, Bo S, Desideri A, Merletti F, Pagano E. Regression models for analyzing costs and their determinants in health care: an introductory review. Int J Qual Health Care. 2011;23(3):331-341.
26. de Oliveira Manoel AL, Goffi A, Zampieri FG, et al. The critical care management of spontaneous intracranial hemorrhage: a contemporary review. Crit Care. 2016;20:272.
27. Levy JH, Faraoni D, Spring JL, Douketis JD, Samama CM. Managing new oral anticoagulants in the perioperative and intensive care unit setting. Anesthesiology. 2013;118(6):1466-1474.
28. Hreinsson JP, Palsdottir S, Bjornsson ES. The Association of Drugs With Severity and Specific Causes of Acute Lower Gastrointestinal Bleeding: A Prospective Study. J Clin Gastroenterol. 2016;50(5):408-413.
29. Dowlatshahi D, Butcher KS, Asdaghi N, et al. Poor prognosis in warfarin-associated intracranial hemorrhage despite anticoagulation reversal. Stroke. 2012;43(7):1812-1817.
30. Peloquin JM, Seraj SM, King LY, Campbell EJ, Ananthakrishnan AN, Richter JM. Diagnostic and Therapeutic Yield of Endoscopy in Patients with Elevated INR and Gastrointestinal Bleeding. Am J Med. 2016;129(6):628-634.
31. Berndtson AE, Coimbra R. The epidemic of pre-injury oral antiplatelet and anticoagulant use. Eur J Trauma Emerg Surg. 2014;40(6):657-669.
32. Dasta JF, McLaughlin TP, Mody SH, Piech CT. Daily cost of an intensive care unit day: the contribution of mechanical ventilation. Crit Care Med. 2005;33(6):1266-1271.
33. Flibotte JJ, Hagan N, O'Donnell J, Greenberg SM, Rosand J. Warfarin, hematoma expansion, and outcome of intracerebral hemorrhage. Neurology. 2004;63(6):1059-1064.
34. Hashash JG, Shamseddeen W, Skoury A, Aoun N, Barada K. Gross lower gastrointestinal bleeding in patients on anticoagulant and/or antiplatelet therapy: endoscopic findings, management, and clinical outcomes. J Clin Gastroenterol. 2009;43(1):36-42.
35. Lopez-Lopez JA, Sterne JAC, Thom HHZ, et al. Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis. BMJ. 2017;359:j5058.
36. Tritschler T, Kraaijpoel N, Le Gal G, Wells PS. Venous Thromboembolism: Advances in Diagnosis and Treatment. JAMA. 2018;320(15):1583-1594.
37. Charlton B, Adeboyeje G, Barron JJ, Grady D, Shin J, Redberg RF. Length of hospitalization and mortality for bleeding during treatment with warfarin, dabigatran, or rivaroxaban. PLoS One. 2018;13(3):e0193912.
38. Milling TJ, Fromm C, Ganetsky M, Pallin DJ, Cong J, Singer AJ. Management of Major Bleeding Events in Patients Treated With Dabigatran for Nonvalvular Atrial Fibrillation: A Retrospective, Multicenter Review. Ann Emerg Med. 2017;69(5):531-540.
39. Jun M, Lix LM, Durand M, et al. Comparative safety of direct oral anticoagulants and warfarin in venous thromboembolism: multicentre, population based, observational study. BMJ. 2017;359:j4323.
 

    This eLearning portal is powered by:
    This eLearning portal is powered by MULTIEPORTAL
Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.


Save Settings